Learning Objectives
At the conclusion of this activity, participants will be able to:
  • Review conventional therapies for mUBC currently employed in community urology practice.
  • Explore FDA-approved immune checkpoint inhibitors (ICIs) used in mUBC regarding mechanism of action, dosing, and applications for use..
  • Consider the evolving roles of ICIs in multimodal and/or combination regimens, including use earlier in the disease course in BCG-unresponsive disease.
  • Anticipate and appropriately manage adverse events that may occur in the use of ICIs in the patient with UBC.
  • Incorporate available patient education for immunotherapies used in UBC, including education on immune-related adverse events and role of the interprofessional bladder cancer team.
  • Monitor and review ongoing advanced bladder cancer trials with real time discussion of evidence-based data about new therapies.